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Abstract 
Introduction: Biologic therapy has 
revolutionalised the treatment of moderate to severe 
psoriasis leading to improved clinical outcomes and 
quality of life scores. This study aims to determine 
current biologic use in psoriatic patients at our 
Dermatology department at Sir Paul Boffa hospital, 
Malta. 
Method: All patients who were administered 
biologic therapy for psoriasis in Malta until the end 
of 2014 were included. Data included demographic 
details, disease duration and severity, biologic use 
and duration, previously attempted treatments, side 
effects, early and late response to biologic using 
Psoriasis Area Severity Index (PASI) scores and 
Dermatology Life Quality index (DLQI) scores.  
 
 
 
 
Results: A total of 36 patients were started on a 
biologic between 2009 and 2014 for psoriasis 
(M:25, F:11) with a mean age of 46.9 years. These 
included etanercept (n=22), infliximab (n=8), 
adalimumab (n=4) and ustekinumab (n=2). 
Secondary failure was the main reason why 
biologics were stopped and switched. Most patients 
had an improvement in their PASI scores after 2 to 
4 weeks of starting the biologic and had a PASI 90 
score improvement. All patients had more than a 5 
point improvement in DLQI score.  
Discussion: Biologic use in our department is 
on the increase. Our patients had considerable 
improvements in their PASI and DLQI scores. 
Secondary failures have occurred usually after 2 to 
4 years and switching has yielded positive results. 
Biologics are expensive drugs and recently we have 
switched to cheaper biosimilars. Doctors should be 
aware of the treatment options available for 
psoriasis patients, their possible side effects and 
when to refer to our department. In most cases a 
satisfactory response can be achieved.  
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Introduction  
Treatment of psoriasis has improved 
dramatically over the past few years with new 
options becoming readily available. First line 
treatment includes topical therapy followed by 
ultraviolet (UV) therapy, with acitretin and the oral 
immunomodulators methotrexate and ciclosporin, 
as second line interventions.1 Biologics have 
revolutionised the management of severe psoriasis 
offering improved clinical outcomes and quality of 
life scores. They target specific immune pathways 
in the pathophysiology of psoriasis. These are 
expensive drugs, with typical drug cost ranging 
from 10,000€ to 18,000€ per patient per year.2 
Current local guidelines (based on European 
and UK guidelines) recommend four biological 
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agents in psoriasis. These are indicated in patients 
with moderate to severe psoriasis who have failed 
or are intolerant of other treatment options. These 
include infliximab, etanercept, adalimumab and 
ustekinumab.1,3 Secukinumab and the cheaper 
biosimilars of infliximab have also been recently 
approved for use in psoriasis.4 New biologic agents 
are constantly being developed targeting different 
immune pathways (Table 1).  A cheaper biosimilar 
of adalimumab is expected to be available in 2018 
when the European patent of the originator drug 
(Humira©) expires. 
 
 
Table 1: Biologics approved in psoriasis, year of FDA approval, mode of action and other approved 
indications (until date of submission) 
 
Since biologics are expensive drugs, cost 
effectiveness is an important factor to consider in 
the commencement and availability of these drugs. 
Clear evidence-based eligibility criteria are 
important to target the appropriate psoriatic 
population.  
The Psoriasis Area Severity Index (PASI) score 
is used to assess disease severity and response to 
treatment in psoriasis.  A PASI score of  ≥10 (range 
0–72) has been shown to correlate with a number of 
indicators commonly associated with severe disease 
such as need for hospital admission or use of 
systemic therapy.1 Satisfactory response is usually 
considered to be a 75%, or even better, a 90% 
improvement as compared to baseline score. This is 
reported as PASI 75 and PASI 90 respectively. The 
Dermatology Life Quality index (DLQI) score is a 
validated tool to assess the impact of skin diseases 
ranging from 0 to 30, with scores more than 10 
indicating a significant impact on quality of life. 
Biologic use in Malta started in 2009 and this 
study gives an overview of the patient 
characteristics and clinical outcomes to date. 
 
Aim 
A cross sectional study to determine current 
biologic use in psoriasis: a local perspective. 
 
Method 
All patients who were administered biologic 
therapy for psoriasis in Malta until the end of 2014 
were included in the study. Patients who were 
started on a biologic for psoriatic arthritis by the 
rheumatologists were excluded. Data collected 
included gender, age, nationality, biologic used, 
date of commencement, concomitant medications, 
disease duration prior to biologic, associated co-
morbidities, previously attempted treatments, 
reason for stopping previous treatments, 
investigations before starting a biologic, early and 
late response to biologic using PASI and DLQI 
scores and side effects reported.  
Biologics for Psoriasis 
(Year of FDA approval) 
Mode of Action, Dose and 
Administration 
Other Approved Indications 
1. Etanercept (Enbrel®)  
 (2004); adults and 
 children >6yrs 
TNF alpha blocker; 50mg (0.8mg/kg) s.c. 
once a week 
Rheumatoid arthritis, Psoriatic arthritis, Juvenile 
Idiopathic Arthritis, Ankylosing spondylitis  
2. Infliximab (Remicade®) 
 (2006) 
 RemsimaTM(EMA 
 approved 2013)  
 InflectraTM (EMA approved 
 2013) 
 
TNF alpha blocker; 5mg/kg i.v. infusion at 
weeks 0, 2, 6 and then every 8 weeks 
Rheumatoid Arthritis , Ankylosing spondylitis, Psoriatic 
arthritis, Inflammatory Bowel Disease  
3. Adalimumab (Humira®) 
 (2008) 
TNF alpha blocker; 80mg s.c., followed by 
40mg every 2 weeks  
Rheumatoid arthritis, Juvenile Idiopathic Arthritis, 
Psoriatic arthritis, Ankylosing spondylitis, Inflammatory 
Bowel Disease 
4. Ustekinumab (Stelara®) 
 (2009) 
Interleukin 12 & 23 blocker;  
45mg (90mg if >100kg) s.c., repeated 
after 4 weeks, and then every 12 weeks 
Psoriatic arthritis 
5. Secukinumab (Cosentyx®) 
 (2015) 
Interleukin 17A blocker; 300mg s.c. at 
weeks 0, 1, 2, and 3 and then every 4 
weeks 
Nil 
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Results 
There were a total of 36 psoriasis patients who 
were started on a biologic between 2009 and 2014 
(N=36); 25 of the patients were male, 11 were 
female. They were all patents with stable chronic 
plaque psoriasis and none had the erythrodermic or 
pustular forms. Twenty-two of these patients were 
on etanercept, 8 patients were on infliximab, 4 
patients were on adalimumab and 2 patients were 
on ustekinumab. The biologic was indefinitely 
discontinued in 12 out of these 36 patients. Reasons 
for discontinuation included patients going abroad 
indefinitely, death from other causes, non-
compliance, patient refusal and worsening of heart 
failure post myocardial infarction.  In 2014, there 
were 24 patients who were on biologics for 
psoriasis: 14 were on etanercept, 6 were on 
infliximab and 4 on adalimumab.  
The ages of the 36 patients ranged from 19 to 
70 years, with a mean age of 46.9 years and a 
median of 46 years. Twenty-nine of the patients 
were Maltese, two were Canadian, three patients 
were from the UK and two patients were Italian. 
The patients were on a variety of concomitant 
medications with methotrexate being the 
commonest (n=14). Disease duration prior to 
biologic therapy ranged from 2 to 55 years, with a 
mean of 16.7 years and a median of 14 years. Six of 
the patients had psoriatic arthritis as a later co-
morbidity, but were started on a biologic by a 
dermatologist.  
Psoriatic treatments attempted before the 
current biologic included: phototherapy [narrow 
band UVB (28) or psoralen UVA (4)], methotrexate 
(29), acitretin (16), ciclosporin (15), etanercept (4), 
infliximab (2) and ustekinumab (2). The reason for 
stopping these medications included: inadequate 
control (24) and side-effects from methotrexate (6), 
ciclosporin (5) and acitretin (4). Secondary failure 
was the main reason why biologics were stopped 
and switched.  
All patients had routine bloods, hepatitis 
screen, tuberculosis screen (Mantoux or 
Quantiferon and Chest X-ray) taken, according to 
protocol. HIV testing is done in high risk patients 
and ANA testing is carried out if indicated. Patients 
on infliximab are seen every two months in the 
dermatology ward whilst the patients on other 
biologics are usually seen according to response and 
and according to whether they are on concomitant 
methotrexate. Quantiferon test is not done annually 
and none of the patients had latent TB. 
Most patients had an improvement in their 
PASI scores after 2 to 4 weeks of starting the 
biologic. Currently, of the 14 patients on etanercept, 
57% (n=8) achieved a PASI 90, 29% (n=4) have a 
PASI 75 and 14% (n=2) had secondary failure after 
2 years. Of the 8 patients on Infliximab, 63% (n=5) 
had a PASI 90, 25% (n=2) had a PASI 75 and 13% 
(n=1) had secondary failure after 1 year. There were 
4 patients started on adalimumab in 2014; 3 of them 
achieved a PASI 90 and 1 patient achieved a PASI 
75. All our patients had more than a 5 point 
improvement in DLQI score. Facial and periorbital 
swelling, lethargy and a chest infection were 
reported as possible side effects with etanercept. No 
side effects were reported for infliximab, 
adalimumab and ustekinumab. Injection site or 
infusion reactions, reactivation of tuberculosis, 
severe infections and sepsis were never reported as 
side effects for any biologic used.  
 
Discussion 
Biologic use in our department is on the 
increase but is heavily determined by the treatment 
options listed on the national health formulary and 
available resources. 
Biologic use for psoriasis in Malta started in 
2009, with etanercept being the first biologic 
available, followed by infliximab in 2011 and later 
adalimumab in 2014. Etanercept stopped being 
available for new psoriasis applications in 2013, but 
patients doing well on etanercept continued to 
receive it. Ustekinumab was never available on the 
national health system - the two patients on 
ustekinumab in this study had the drug provided for 
them through private arrangements which were 
subsequently withdrawn. In our study, patients on 
biologics were predominantly male (69% male, 
31% female), suggesting that men are at a higher 
risk for severe psoriasis. This is also the situation in 
other countries.5-6 
This study shows that our department is 
following the latest guidelines. Our patients are first 
treated with topical therapy, then phototherapy or 
second line agents including methotrexate, acitretin 
and ciclosporin. If these fail, are contraindicated or 
cause intolerable side effects, a biologic is started. It 
is interesting to note that most patients had an 
adequate (≥75% decrease in PASI score) and 
sometimes impressive response initially to the 
biologic, with most patients achieving complete or 
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almost complete clearance of their psoriasis. There 
were a few patients whose psoriasis started to 
relapse (described as secondary failure) after 2 to 4 
years of successful treatment with the biologic, that 
necessitated switching to another biologic to 
maintain control of the psoriasis. Switching 
between biologics that act on the TNF alpha 
pathway, such as etanercept to infliximab or 
adalimumab, and infliximab to adalimumab or 
etanercept, has yielded positive results in these few 
cases in our department.  
There is evidence that concomitant treatment 
with methotrexate might increase biologic efficacy 
by reducing the antigenicity towards biologics and 
their clearance.7-8 Sixty-one percent of our patients 
on biologics are on concomitant methotrexate 
therapy, usually at low dose (often 7.5 mg per 
week). In our experience there were never any 
serious side effects reported and this combination 
has been working well. 
In 2015, patients who were started on a 
biologic in the previous years will be kept on the 
same treatment whilst new patients will be started 
on the cheaper biosimilar of infliximab 
(RemsimaTM) as determined by our national health 
system. This should result in a 30 percent decrease 
in the total cost of biologic therapy per patient per 
year. Future considerations to increase cost-
effectiveness of psoriasis treatments include the 
provision of psychological support in this often 
stress-related condition and nursing support with 
topical medications, especially in the elderly. It is 
also important to follow up patients regularly so 
that treatment failures can be identified early and 
treatment changed accordingly. Testing of drug and 
antibody levels will probably play an important role 
in optimizing treatment in the near future. 9-10 For 
example, it has been estimated that one-third of 
patients on standard doses of adalimumab have 
drug levels higher than the therapeutic range.11 
In the case of severe side-effects with 
RemsimaTM, or if primary or secondary failure 
develops to it, an application to the Exceptional 
Medicinal Treatment Committee (Directorate for 
Pharmaceutical Affairs) would need to be made to 
allow switching to another biologic. This could be 
to another TNF alpha blocker (Adalimumab or 
Etanercept) or to a biologic acting on a different 
immune pathway (Ustekinumab or Secukinumab). 
A limitation to the availability of all of these 
biologics on the National Formulary is, of course, 
their high cost. 
 
Conclusion 
Psoriasis is a chronic condition that can have a 
significantly negative impact on quality of life. Our 
patients had considerable improvements in their 
PASI and DLQI scores with biologic treatment. It is 
important that primary care doctors are aware of the 
treatment options available for patients with 
psoriasis, their possible side effects and when to 
refer patients to our department. In most cases a 
satisfactory response can be achieved.  
 
Figure 1: Patient with psoriasis before biologic treatment 
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Figure 2:  Patient clear from psoriasis 6 months after commencing biologic treatment with Ustekinumab 
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